Posted from: Tuesday, May 31, 2016 - 03:40 PM - Present

Approval of Kidney Cancer Drug Lenvima

May 16, 2016 – The U.S. Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for treating patients with advanced renal cell carcinoma (aRCC) in combination with Afinitor® (everolimus – Novartis) following prior anti-angiogenic therapy. Lenvima is an oral multiple receptor tyrosine kinase inhibitor manufactured by Eisai. The recommended dose for aRCC is 18mg of Lenvima in combination with 5mg of Afinitor, once daily. Lenvima was previously approved in February 2015 for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Monday, May 22, 2017 - 07:01 AM.